Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

DAMICO JENNIFER B.

The article recommends Pfizer and Medtronic as attractive dividend stocks for long-term investors seeking portfolio stability amid economic uncertainties. Despite recent challenges, both healthcare leaders offer compelling dividend yields (6.8% and 3.6% respectively) and have strong pipelines and growth opportunities that could drive returns over the next decade.

2 High-Yield Dividend Stocks to Buy and Hold for a Decade

Pfizer stock has declined over 50% from its 2021 peak, driving its dividend yield to 6.8%. While the company faces near-term headwinds from patent expirations on key drugs and lacks immediate replacements, analysts suggest long-term investors should view this as a turnaround opportunity. With a century-long track record and several drug trials scheduled for 2026, Pfizer is expected to navigate this difficult period and return to growth, potentially offering both income and capital appreciation.

Could Pfizer Stock Be Your Ticket to Generational Wealth?

Retiring on $500,000 is possible with the right strategy. The article recommends three high-dividend income stocks that could help achieve this goal: Ares Capital (10.6% yield), Energy Transfer (7.2% yield), and Pfizer (6.8% yield). Combined with Social Security benefits, these stocks could generate sufficient income for retirement, though diversification beyond three stocks is essential.

Want to Retire on $500,000? 3 Stocks to Buy and Never Sell

Eli Lilly is thriving in the GLP-1 weight-loss drug market with strong sales growth, but offers minimal dividend yield of 0.6%. Pfizer, struggling with patent expirations and GLP-1 setbacks, offers a much higher 6.6% dividend yield. While Pfizer faces near-term headwinds, income-focused investors willing to accept risk may find value in its substantial dividend, though the payout ratio exceeding 100% raises concerns.

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will depart in August, raising investor concerns about leadership continuity and the company's ability to meet 2026 guidance. While recent drug approvals strengthen the pipeline, the CFO transition creates uncertainty around financial execution and earnings recovery.

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

The FDA approved an expanded indication for Merck's Capvaxive pneumococcal vaccine, extending its use to children and adolescents ages 2-17 with chronic conditions. The approval was based on Phase 3 STRIDE-13 trial data and makes Capvaxive the only pneumococcal conjugate vaccine specifically studied and indicated for this patient group in the U.S. The vaccine covers serotypes associated with approximately 79% of invasive pneumococcal disease cases among at-risk children.

FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens

Sandman

Trading & Investing Education 
Inventor : Ripster Cloud System  
Founder: Tenet Trade Group
https://t.co/0qpaN2fM0W
 https://t.co/GP2vE0fon3

Pfizer Inc (PFE) Stock Price, Analysis & Trade Signals